CymaBay Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

CymaBay Therapeutics

09/08/2023 01:50

* CymaBay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
10. 
    * The Newark California California-based  company is
expected to
report revenue of $9.898 million, according to the mean estimate
from 10 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for CymaBay
Therapeutics Inc
is for a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CymaBay
Therapeutics Inc is $16​, above​ its last closing price
of $12.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.11       -0.09      -0.29     Missed  -230.4
 Dec. 31 2023  -0.30       -0.30      -0.30     Met     0
 Sep. 30 2022  -0.30       -0.30      -0.28     Beat    7​
 Jun. 30 2022  -0.30       -0.30      -0.31     Missed  -3.8
 ​​Mar.        -0.31       -0.31      -0.32     Missed  -3.3
 31 2022                                                
 Dec. 31 2021              -0.26      -0.34     Missed  -30.1​
 Sep. 30 2021  -0.28       -0.26      -0.33     Missed  -25.4
 Jun. 30 2021  -0.27       -0.27      -0.34     Missed  -27
 This summary was machine generated August 9 at 00:50 GMT.  All
figures in US dollars  unless otherwise stated